Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.41 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552453 | 1.00 | OPRM1 (0.43) | OPRM1OPRK1APLNREPHA2NMUR2 | |
| SCHEMBL1552452 | 0.94 | OPRM1 (0.44) | OPRM1OPRK1APLNREPHA2 | |
| SCHEMBL1552455 | 0.94 | OPRM1 (0.44) | OPRM1OPRK1APLNREPHA2 | |
| SCHEMBL31124688 | 0.93 | OPRM1 (0.41) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL29802182 | 0.92 | OPRM1 (0.44) | OPRM1OPRK1EPHA2NMUR2NMUR1 | |
| SCHEMBL10340262 | 0.91 | ACE (0.42) | OPRM1OPRK1APLNREPHA2 | |
| SCHEMBL4190053 | 0.91 | ACE (0.42) | OPRM1OPRK1APLNREPHA2 | |
| SCHEMBL4190057 | 0.91 | ACE (0.42) | OPRM1OPRK1APLNREPHA2 | |
| SCHEMBL7444428 | 0.91 | ACE (0.42) | OPRM1OPRK1APLNREPHA2 | |
| SCHEMBL27445701 | 0.91 | ACE (0.42) | OPRM1OPRK1APLNREPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747264-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | University of Reading (GB) | 2026-05-27 | — | — | EP | claimed |
| WO-2025037123-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | UNIVERSITY OF READING (GB) | 2025-02-20 | — | — | WO | claimed |
| EP-4747264-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | University of Reading (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025037123-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | UNIVERSITY OF READING (GB) | 2025-02-20 | — | — | WO | disclosed |
| US-20240304334-A1 | CLOTTABILITY-BASED PERSONALIZED TREATMENT (CPT) SYSTEM | PUN SAN (CH) | 2024-09-12 | — | — | US | disclosed |
| CN-115894625-B | Polypeptide with anti-aging effect and application thereof | 桂林医学院 | 2024-08-27 | — | — | CN | disclosed |
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117561450-A | Personalized Therapy (CPT) system based on clotting capabilities | 潘山 | 2024-02-13 | — | — | CN | disclosed |
| CN-115894625-A | Polypeptide with anti-aging effect and application thereof | 桂林医学院 | 2023-04-04 | — | — | CN | disclosed |
| CN-115702161-A | Peptide compositions and methods for inhibiting nicotinic acetylcholine receptor activity | 格罗制药公司 | 2023-02-14 | — | — | CN | disclosed |
| EP-1833571-B1 | COSMETIC COMPOSITION FOR SKIN APPLICATION SUITABLE FOR RELAXING EXPRESSION WRINKLES | LABO COSPROPHAR AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-7846483-B2 | Cosmetic composition for skin application suitable for relaxing expression wrinkles | LABO COSPROPHAR AG (CH) | 2010-12-07 | — | — | US | disclosed |
| EP-1833571-A1 | COSMETIC COMPOSITION FOR SKIN APPLICATION SUITABLE FOR RELAXING EXPRESSION WRINKLES | LABO Cosprophar AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-20070148118-A1 | Cosmetic composition for skin application suitable for relaxing expression wrinkles | LABO COSPROPHAR AG (CH) | 2007-06-28 | — | — | US | disclosed |
| WO-2006069608-A1 | COSMETIC COMPOSITION FOR SKIN APPLICATION SUITABLE FOR RELAXING EXPRESSION WRINKLES | LABO COSPROPHAR AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | OPRM1 2825/4885OPRK1 2549/4885APLNR 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.